Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab/Lenvatinib Combined With TACE in Borderline Resectable HCC
NCT05042336Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Sichuan University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05042336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042336.